{"entity":{"id":"nct06953089","kind":"trial","name":"DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors","aka":[],"tldr":"A phase 2 trial of BNT324 and PM8002 in advanced solid tumours, run by DualityBio Inc., now recruiting.","summary":"DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors is a phase 2 interventional study registered as NCT06953089 by DualityBio Inc., with 450 participants planned, started 2025-07-18 and due to reach its primary completion in 2030-06-30. Interventions recorded: DB-1311/BNT324, BNT327 and DB-1305/BNT325.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06953089","url":"https://clinicaltrials.gov/study/NCT06953089"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["bnt324","pm8002"],"companies":["dualitybio","biontech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06953089","phase":"2","setting":"A Phase II, Multicenter, Open-Label Trial of DB-1311 in Combination With BNT327 or DB-1305 in Participants With Advanced/Metastatic Solid Tumors","sponsor":"DualityBio Inc.","enrolled":450,"outcomes":[]},"route":"/trials/nct06953089/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"bnt324","kind":"drug","name":"BNT324","route":"/drugs/bnt324/"},{"id":"pm8002","kind":"drug","name":"PM8002","route":"/drugs/pm8002/"}],"company":[{"id":"biontech","kind":"company","name":"BioNTech","route":"/companies/biontech/"},{"id":"dualitybio","kind":"company","name":"Duality Biotherapeutics","route":"/companies/dualitybio/"}]}}